Revvity (RVTY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 Apr, 2026Opening remarks and agenda
Meeting conducted virtually with introductions by General Counsel and CEO, outlining the agenda and board member qualifications.
Deloitte & Touche LLP partner present to address auditor-related questions.
Board and executive committee updates
Board nominees included experienced leaders from life sciences, finance, technology, and investment sectors.
All 10 directors were nominated for reelection for a one-year term.
Shareholder proposals
Shareholder proposal requested executives retain at least 25% of net after-tax shares until retirement and restrict hedging.
Proposal aimed to align executive incentives with long-term performance.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Revvity
- Q2 2026 saw strong growth, margin expansion, and raised outlook, led by Diagnostics strength.RVTY
Q2 2026 - Life sciences and software growth accelerate as pharma biotech recovers and AI adoption expands.RVTY
Citi Annual Global Healthcare Conference 2025 - Strong growth, portfolio optimization, and innovation drive optimism for sustained margin expansion.RVTY
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Divestiture of China immunodiagnostics boosts growth outlook; AI and software launches drive optimism.RVTY
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 7%, strong organic growth, and China divestiture shapes 2026 outlook.RVTY
Q1 2026 - Key votes include director elections, auditor ratification, and by-law amendment for special meetings.RVTY
Proxy Filing - Board recommends all management proposals, including by-law amendment, and opposes stock retention proposal.RVTY
Proxy Filing - Targeting 6%-8% organic growth and margin expansion through innovation and operational synergies.RVTY
Investor Day 2024 - Q3 revenue up 2% to $684M, adjusted EPS $1.28, and new $1B share repurchase program.RVTY
Q3 2024